ABIN1449244
antibody from antibodies-online
Targeting: CD274
B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1
Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1449244 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-CD274 Molecule (CD274) (Extracellular Domain) antibody
- Antibody type
- Monoclonal
- Description
- Protein A agarose
- Reactivity
- Human
- Host
- Mouse
- Epitope
- Extracellular Domain
- Isotype
- IgG
- Antibody clone number
- 27A2
- Vial size
- 0.1 mg
- Storage
- Upon receipt, store (in aliqouts) at -20°C.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Overall survival and PD-L1 expression in metastasized malignant melanoma.
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation.
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
Hormone in the hot seat.
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C
Cancer 2011 May 15;117(10):2192-201
Cancer 2011 May 15;117(10):2192-201
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y
Cancer 2010 Apr 1;116(7):1757-66
Cancer 2010 Apr 1;116(7):1757-66
The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation.
Schuchmann M, Meyer RG, Distler E, von Stebut E, Kuball J, Schnürer E, Wölfel T, Theobald M, Konur A, Gregor S, Schreiner O, Huber C, Galle PR, Otto G, Herr W
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008 Nov;8(11):2434-44
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008 Nov;8(11):2434-44
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S
Proceedings of the National Academy of Sciences of the United States of America 2007 Feb 27;104(9):3360-5
Proceedings of the National Academy of Sciences of the United States of America 2007 Feb 27;104(9):3360-5
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD
Nature 2006 Sep 21;443(7109):350-4
Nature 2006 Sep 21;443(7109):350-4
Hormone in the hot seat.
Mandavilli A
Nature medicine 2006 Jan;12(1):8-9
Nature medicine 2006 Jan;12(1):8-9
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED
Proceedings of the National Academy of Sciences of the United States of America 2004 Dec 7;101(49):17174-9
Proceedings of the National Academy of Sciences of the United States of America 2004 Dec 7;101(49):17174-9
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T
The Journal of experimental medicine 2000 Oct 2;192(7):1027-34
The Journal of experimental medicine 2000 Oct 2;192(7):1027-34
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- FACS